FY2026 EPS Estimates for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Erste Group Bank upped their FY2026 earnings estimates for shares of Gilead Sciences in a report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $8.67 for the year, up from their prior forecast of $8.65. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

GILD has been the subject of a number of other research reports. TD Cowen increased their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Cantor Fitzgerald upped their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Finally, Daiwa Securities Group boosted their price objective on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Price Performance

Shares of GILD opened at $134.25 on Friday. The firm has a 50-day simple moving average of $144.09 and a two-hundred day simple moving average of $128.57. The stock has a market cap of $166.63 billion, a PE ratio of 19.83, a P/E/G ratio of 1.79 and a beta of 0.37. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. J. Derek Lewis & Associates Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $346,000. Rockefeller Capital Management L.P. boosted its holdings in Gilead Sciences by 34.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 88,893 shares of the biopharmaceutical company’s stock valued at $10,911,000 after purchasing an additional 22,559 shares in the last quarter. World Investment Advisors increased its stake in Gilead Sciences by 12.7% in the fourth quarter. World Investment Advisors now owns 31,753 shares of the biopharmaceutical company’s stock valued at $3,897,000 after purchasing an additional 3,589 shares during the last quarter. Meadowbrook Advisors Group LLC purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $302,000. Finally, Larry Mathis Financial Planning LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $593,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares in the company, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 309,280 shares of company stock valued at $44,068,850. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Ouro Medicines for up to about $2.18B to expand its inflammation/immunology franchise, strengthening longer‑term growth optionality beyond established HIV and antiviral products. Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
• Positive Sentiment: Gilead has been adding immunology and CAR‑T assets to diversify its pipeline and bolster oncology exposure — a strategic shift that could lift medium/long‑term revenue growth if integration and clinical readouts succeed. Can Gilead’s Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
• Positive Sentiment: Gilead recently reported an earningsbeat and set FY‑2026 EPS guidance in the $8.45–$8.85 range, signaling stable profitability and management confidence; consensus still trails that guidance, which supports valuation. Gilead Sciences Trading / Company Report
• Positive Sentiment: Erste Group nudged up its FY‑2026 EPS forecast for Gilead, a modest analyst raise that reinforces hopes for better-than-consensus earnings next year.
• Neutral Sentiment: Analyst consensus (average brokerage recommendation) sits at a Buy — helpful context but potentially already reflected in the share price; take analyst ratings as background, not a catalyst. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Zacks highlights Gilead as a value‑oriented pick under its style scores, which may attract income/value investors but is not an immediate price driver. Here’s Why Gilead Sciences (GILD) is a Strong Value Stock
• Neutral Sentiment: Industry event notices (e.g., SK pharmteco symposium) are peripheral to Gilead’s near‑term stock movement and unlikely to be material. SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium
• Negative Sentiment: Market skepticism: analyst optimism and “Buy” consensus could be priced in, and investors may be trimming positions after recent gains (Gilead has traded near a 52‑week high in the past year), leading to downward pressure. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Deal risk and near‑term cost: the ~ $2.2B acquisition and other purchases increase upfront cash outlays and execution risk (integration, trial outcomes), which can weigh on the stock until benefits are demonstrated.
• Negative Sentiment: Technical/flow factors: trading volume is below the stock’s average and the price is below the 50‑day moving average, consistent with the current down move and limited buying momentum.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.